Max Nisen, Columnist

Novo Nordisk's Deal Discipline Is Behind the Times

January 29, 2018 at 5:01 PM UTC

Max Nisen is a healthcare analyst at Bloomberg Intelligence. He previously wrote for Bloomberg Opinion, Quartz and Business Insider.

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

If Novo Nordisk A/S is bargain-hunting, its timing is bad.

Sanofi on Monday said it would pay $4.8 billion to buy Belgian biotech Ablynx NV, outbidding Novo Nordisk so badly that the Danish pharma giant scrapped plans to raise a lowball $3.1 billion initial bid and conceded defeat.